Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD3293 with Itraconazole, Diltiazem, and Midazolam
NCT02010970Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lanabecestat in Alzheimer's disease (AD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve at Day 17 and Maximum Concentration at Day 17. Started Dec 2013; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02010970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02010970.